Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Wells Fargo analyst Vik Chopra has assigned their bullish stance on MASI stock, giving a Buy rating yesterday. Vik Chopra has given his Buy ...

Revenue: US$504.6m (up 5.4% from 3Q 2023). Net income: US$9.80m (down 7.5% from 3Q 2023). Profit margin: 1.9% (down from 2.2% in 3Q 2023). The decrease in margin was driven by higher expenses. EPS ...

Unrecognized Contract Revenues: $1.65 billion as of the end of Q3. Masimo Corp (NASDAQ:MASI) reported healthcare revenues of $343 million for the third quarter, representing a 12% growth compared ...

Q3 2024 Earnings Call Transcript November 5, 2024 Masimo Corporation beats earnings expectations. Reported EPS is $0.98, expectations were $0.84. Operator: Ladies and gentlemen, good afternoon, and ...

Masimo sells a range of devices used for patient monitoring that feature a proprietary pulse oximetry technology called Signal Extraction Technology (SET). In the latest update on that patent spat ...

RA takes a toll on mental health, with some estimates that up to 22% of RA patients have depression. In one study, more than 50% of RA patients who reached remission sustained it for at least two ...

The Expert Patients Programme (EPP) is a six-week course for anyone living with one or more long term health conditions such as asthma, chronic fatigue, COPD, depression, diabetes, heart disease, MS, ...